{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:21:02Z","timestamp":1790662862552,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ecl.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:16:03Z","timestamp":1621448163000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Updates on Osteoporosis in Men"],"prefix":"10.1016","volume":"50","author":[{"given":"Dima L.","family":"Diab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib1","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","year":"2000","journal-title":"NIH Consensus Statement"},{"key":"10.1016\/j.ecl.2021.03.001_bib2","unstructured":"Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK45513\/pdf\/Bookshelf_NBK45513.pdf\/. Accessed October 25, 2020."},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650100202","article-title":"How many women have osteoporosis now?","volume":"10","author":"Melton","year":"1995","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.001_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/oxfordjournals.aje.a009541","article-title":"Risk factors for increased bone loss in an elderly population: the Rotterdam Study","volume":"147","author":"Burger","year":"1998","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2021.03.001_bib6","unstructured":"Available at: https:\/\/www.cdc.gov\/nchs\/fastats\/osteoporosis.htm\/. Accessed October 25, 2020."},{"key":"10.1016\/j.ecl.2021.03.001_bib7","first-page":"65","article-title":"The clinical epidemiology of male osteoporosis: a review of the recent literature","volume":"7","author":"Willson","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.001_bib8","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion","year":"2003","journal-title":"Am Fam Physician"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.001_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s001980200100","article-title":"Survival and potential years of life lost after hip fracture in men and age-matched women","volume":"13","author":"Trombetti","year":"2002","journal-title":"Osteoporos Int"},{"issue":"18","key":"10.1016\/j.ecl.2021.03.001_bib10","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/archinte.163.18.2165","article-title":"Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation","volume":"163","author":"Feldstein","year":"2003","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.001_bib11","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2021.03.001_bib12","unstructured":"Available at: https:\/\/www.iscd.org\/official-positions\/2019-iscd-official-positions-adult\/. Accessed October 25, 2020."},{"issue":"4","key":"10.1016\/j.ecl.2021.03.001_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4158\/EP.12.4.436","article-title":"Secondary osteoporosis: a review of the recent evidence","volume":"12","author":"Painter","year":"2006","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4158\/EP12059.RA","article-title":"Secondary causes of osteoporosis","volume":"19","author":"Hudec","year":"2013","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0889-8529(02)00062-2","article-title":"Secondary osteoporosis","volume":"32","author":"Stein","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4158\/EP.ep.14.3.293","article-title":"Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients","volume":"14","author":"Geller","year":"2008","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.001_bib17","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.001_bib18","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ageing\/afs094","article-title":"Who should receive calcium and vitamin D supplementation?","volume":"41","author":"Verbrugge","year":"2012","journal-title":"Age Ageing"},{"issue":"9588","key":"10.1016\/j.ecl.2021.03.001_bib20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","article-title":"Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis","volume":"370","author":"Tang","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11914-996-0028-z","article-title":"The role of vitamin D for bone health and fracture prevention","volume":"4","author":"Holick","year":"2006","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.001_bib22","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1210\/jc.2003-030604","article-title":"Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam","volume":"88","author":"Visser","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.001_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1024\/0300-9831.78.6.286","article-title":"Importance of vitamin D and calcium at older age","volume":"78","author":"Bischoff-Ferrari","year":"2008","journal-title":"Int J Vitam Nutr Res"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4065\/81.3.353","article-title":"High prevalence of vitamin D inadequacy and implications for health","volume":"81","author":"Holick","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1359\/jbmr.2003.18.2.343","article-title":"Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial","volume":"18","author":"Bischoff","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"issue":"16","key":"10.1016\/j.ecl.2021.03.001_bib26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of Vitamin D on falls: a meta-analysis","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.001_bib27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.2000.15.6.1113","article-title":"Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women","volume":"15","author":"Pfeifer","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00198-008-0662-7","article-title":"Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals","volume":"20","author":"Pfeifer","year":"2009","journal-title":"Osteoporos Int"},{"issue":"7387","key":"10.1016\/j.ecl.2021.03.001_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","article-title":"Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial","volume":"326","author":"Trivedi","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.001_bib30","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.03.001_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-0-387-77574-6_5","article-title":"Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes","volume":"624","author":"Bischoff-Ferrari","year":"2008","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.001_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1210\/jc.2011-2601","article-title":"Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited","volume":"97","author":"Holick","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.001_bib33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/BOR.0b013e328362164d","article-title":"Osteoporosis in men","volume":"25","author":"Ebeling","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4158\/EP13114.RA","article-title":"Osteoporosis in men","volume":"19","author":"Watts","year":"2013","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.001_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2021.03.001_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2474-6-39","article-title":"Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women","volume":"6","author":"Sawka","year":"2005","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib37","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MJT.0000000000000446","article-title":"Alendronate for the treatment of osteoporosis in men: a meta-analysis of randomized controlled trials","volume":"24","author":"Xu","year":"2017","journal-title":"Am J Ther"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.001_bib38","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70\u00a0mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial","volume":"36","author":"Stoch","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.001_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.001_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"18","key":"10.1016\/j.ecl.2021.03.001_bib43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1759720X13500861","article-title":"Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence","volume":"5","author":"Sim","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.beem.2018.05.007","article-title":"Update on osteoporosis in men","volume":"32","author":"Adler","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.001_bib47","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/annrheumdis-2013-205080","article-title":"Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw","volume":"73","author":"Kharazmi","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.001_bib48","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.001_bib49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.001_bib50","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.001_bib53","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.001_bib54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14656566.2018.1428559","article-title":"New and developing pharmacotherapy for osteoporosis in men","volume":"19","author":"Gennari","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.001_bib55","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A\u00a0Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","article-title":"Patient adherence to osteoporosis medications: problems, consequences and management strategies","volume":"24","author":"Papaioannou","year":"2007","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.001_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11914-006-0011-8","article-title":"Review of adherence to medications for the treatment of osteoporosis","volume":"4","author":"Gold","year":"2006","journal-title":"Curr Osteoporos Rep"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.001_bib58","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4158\/1934-2403-25.10.1077","article-title":"Practice patterns in the treatment of male osteoporosis","volume":"25","author":"Papaleontiou","year":"2019","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.001_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ecl.2007.03.008","article-title":"Osteoporosis in men","volume":"36","author":"Gennari","year":"2007","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292100013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292100013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:30Z","timestamp":1760175930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985292100013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S088985292100013X"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Osteoporosis in Men","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}